AstraZeneca is seeking approval to sell cheap off-patent drugs to Brazil.
阿斯利康公司也寻求在巴西销售那些专利保护即将到期的产品。
OBJECTIVE: To offer references for clinical rational use of Chinese patent drugs.
前言：目的：为临床合理应用中成药提供借鉴。
These drugs should be a focus of cancer treatment programmes, rather than expensive on-patent drugs.
治疗计划应尽量考虑使用这样的药物，而不是那些天价专利药品。
Ginkgo capsule, one of the Chinese patent drugs, is a new product in new form with few side effects.
银杏叶胶囊是一种新品种、新剂型的中成药，副作用少。
The Chinese patent drugs in clinic is good in stable quality, gentle and reliability, easy to control dosage, and convenience. They have been widely used in many diseases.
中成药在临床应用中具有质量稳定、疗效温和可靠、剂量易控，使用方便等优势，被广泛应用于各科疾病。
The institute has already screened the drugs in development by Roche, another Swiss firm, under a different deal that also involved waiving patent restrictions.
这个机构已经筛选了另一个瑞士公司——罗氏正在开发的药物，这份不同的协议中同样包括放开专利限制。
The reasons are manifold: First, few blockbuster drugs lost their patent protection.
原因是多方面的：首先，一些重点药物失去了专利保护。
Consequently, they could begin to isolate specific chemicals that could be the basis for potential new drugs, which would be easier to patent.
最终他们能够开始分离具体的化学物质，并以此作为基础开发未来的新药物——这些药物将更容易获得专利权。
Unfortunately, these losses have coincided with a decline in R&D productivity: the drugs discovered in the labs are not replacing the value of those medicines losing patent protection.
不幸的是，这种损失恰逢研发生产力的衰退：实验室里研发出药物无法取代那些失去专利保护的药物。
Share prices have taken a beating as the industry has failed to come up with enough promising blockbuster drugs to compensate for the revenue lost when old money-spinners lose their patent protection.
在业界还没有研制出足够有前景的重磅型新药以补偿老的赢利企业失去专利保护时而遭受的亏损，其股价也遭受打击。
Investors had sent Big Pharma a very clear message: Stop spending so much money to create new drugs, even if you're losing exclusivity on your older drugs through the so-called patent cliff.
投资者向医药巨头们传达了一个明确信息：不要再投入巨资用于新药研发，即便公司正在失去旧有药品的专利保护，面临所谓的专利悬崖困境。
The squeeze will get worse as a dozen top-selling drugs lose patent protection over the next two years.
随着十几个畅销药品的专利保护期在今后的两年中逐渐失效，这种榨取行为将会愈演愈烈。
The industry is witnessing increased competition from generic drugs as an unprecedented number of branded medicines lose patent protection.
随着失去专利保护的品牌药物达到前所未有的数量，制药业面临的来自无商标药物的竞争日益激烈。
Billions of dollars of branded blockbuster drugs are due to go off-patent in 2009 and 2010.
价值上万亿美元的名牌药物将在2009年和2010年失去专利保护。
A slew of drugs by Japanese makers will be losing their patent protections shortly.
大量日产药品不久将失去专利保护。
But the only way poor countries can get drugs that result from Shared patent rights is if another country exports those medicines to them under emergency exceptions.
但是穷国可以得到(分享了专利权的)药物的唯一途径就是另外的国家是否能够在紧急事态下向他们出口仿制药物。
The best way out for the established drugs industry would be to find lots of clever new blockbusters to replace the ones going off-patent.
对已成型的制药业来说，最好的方法就是找到许多新的畅销药来取代专利将要过期的药品。
The most egregious offence is the “pay-for-delay” deal, under which a patent-holder pays a maker of generic drugs to delay its launch of a cheap copy.
妨碍仿制药上市最臭名昭著的绊脚石是“付费推迟”协议。根据这项协议，专利持有人可以买通仿制药制造商以推迟其将廉价的复制产品推向市场。
Pfizer sued the two companies in 2005. Local drug makers have stepped up patent challenges in hopes of being allowed to market generic copies of various drugs.
辉瑞2005 年向这两家公司提出起诉．中国地方制药公司已经加大了对专利的挑战，希望获准出售各种药品的复制品。
The trend only looks to continue as the global pharmaceutical industry faces slower pipelines and significantly more drugs come off patent in the next few years.
这一趋势还将继续，因为制药巨头们正面临更新产品线放缓以及未来几年许多药物专利到期的形势。
For example, patients can be treated with lower-cost drugs that are off-patent.
例如，患者可以使用成本较低的专利已过期的药物进行治疗。
Many large pharmaceutical companies are struggling to come up with new blockbuster drugs at a time when existing products are coming off patent protection.
许多大型制药企业现有产品的专利保护即将到期，目前在推出新的主打药物方面有困难。
Case studies of drugs and medical products illustrate the product development-product testing cycle, patent protection, and FDA approval.
药品和医疗产品的案例研究介绍了产品开发，产品测试周期，专利保护，以及FDA的批准。
Case studies of drugs and medical products illustrate the product development-product testing cycle, patent protection, and FDA approval.
药品和医疗产品的案例研究介绍了产品开发，产品测试周期，专利保护，以及FDA的批准。
应用推荐